Cooley, Ogier, Latham & Watkins, Maples and Calder, and Goodwin advise on TriGemX Bio’s business combination with TCGX Acquisition Corp.
TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, have announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named TriGemX Bio, Inc. And is expected to trade on Nasdaq under the new ticker symbol TGEM.
Net proceeds from the transaction are expected to provide the combined company with the capital needed to complete the ongoing elismetrep Phase 3 clinical trials for the acute treatment of migraine and submit a New Drug Application (NDA) for this indication, complete a clinical trial of elismetrep in migraine prevention using a distinct dose and formulation, and enable key commercial readiness activities as the combined company prepares for a potential U.S. launch.
Cooley advised TriGemX Bio on the transaction.
The team was led by Div Gupta, Bill Sorabella, Eric Blanchard, Julia Kim, and Susan Choy.
Michael Bergmann, Christopher Kimball, Madhuri Roy, Alison Freeman-Gleason, Natasha Leskovsek, Sharon Connaughton, Jennifer Shanley, Phil Mitchell, Stephanie Gentile, Todd Gluth, Julie Montejo, Kevin Cheng, Will Friend, Chelsea Braun, Josh Holtzman, Matt Choy, and Calvin Lee provided support.
Ogier (Cayman) LLP acted as Cayman counsel to TriGemX Bio.
Latham & Watkins LLP represented TCGX in the transaction.
The corporate team was led by Houston Partners Ryan Maierson and Ryan Lynch, with Associates Taylor Allison, Cooper Shear, and Luisa Gomez Yokubaitis, with assistance from Zachary Mouton.
Maples and Calder (Cayman) LLP acted as Cayman counsel to TCGX.
Goodwin Procter LLP acted as legal counsel to Jefferies, TD Cowen, Cantor and LifeSci Capital.
